The human kinome is a very large and druggable class of targets with many disease indications. Because of this, the kinome targets account for a significant portion of drug discovery efforts. Kinase inhibitor discovery is a very active area as developers
are exploring more deeply into designing immune-modulatory agents as single or combination therapies, tackling chronic disease indications such as inflammation and CNS disorders, as well as effectively harnessing allosteric modulators, and covalently
binding compounds. Cambridge Healthtech Institute’s 11th Annual Kinase Inhibitor Discovery conference will gather academic and industry leaders to collaborate and discuss advances in kinase drug discovery.
Who should attend: PRESIDENTS, VICE PRESIDENTS, CEOs, CTOs, MEDICINAL CHEMISTS and SCIENTISTS working in drug development from academia, government, or industry
Coverage will include, but is not limited to:
- Tryosine kinase inhibitors
- Covalent kinase inhibitors
- Target covalent inhibitors
- Macrocycle inhibitors
- Reversible inhibitors
- Fragment and structure-based design
- Lead & target optimization
- AK, MAPK, P13K and other kinases
If you would like to submit a proposal to give a presentation at this meeting, please click here.
The deadline for priority consideration is March 21, 2018.
All proposals are subject to review by session chairmen and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
For more details on the conference, please contact:
Vice President, Production
Phone: (+1) 781-972-5423
For partnering and sponsorship information, please contact:
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286